The core strength of our Biologics division is the
ability to develop biosimilar products from the cloning
stage, covering all aspects of development including
establishing biosimilarity in quality, safety & efficacy.
The current Biologics portfolio comprises of peptides
and biosimilars. Three of our peptide products, namely,
Octreotide, Eptifibatide and Bivalirudin have been
commercialized. In the pipeline are eight Biosimilars at
various stages of development. Five of these, GCSF,
PEG-GCSF, hGH, Teriparatide and PDGF–BB are in the
clinical and pre-clinical phases.
Read more...
For more information, Click Here
